Yiming Cell Closes on Tens of Million Yuan Angel Round Financing

According to Lieyunwang.com, Yiming Cell has completed the angel round financing of tens of million yuan, led by Cowin Capital with participation from existing investor Chiron Ventures. Proceeds from the financing will be used to improve the team and upgrade equipment.

Founded in October 2015, Yiming Cell is committed to the development and application of cell and gene therapy technology, and providing overall solutions for gene therapy research and development, clinical application and industrialization. Its business covers the CRO and CDMO services of innovative drugs for cell and gene therapy. 

The team of Yiming Cell composed of experts from Harvard University, Hopkins University, University of Maryland, Columbia University (UBC) and other academicians or researchers with more than 10 years of experience in cell therapy and gene therapy.

"Through communication with various gene therapy companies, we know that everyone is concerned about two things——compliance and cost. Our unique C + A workshop design, absolutely isolated methods of production, and independent GMP system, fully guarantee the production under compliance. Through our efficient, compliance, economic mode of production, Yiming Cell can further promote the development of cell and gene therapy industry in China," said Li Qichen, the co-founder and President of Yiming Cell.

Founded in June 2000, Cowin Capital Group was as China's first professional private placement equity investment company. The company has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 more successfully exit.

Cowin Capital focuses on investing in pioneering enterprises on a long-term basis, always keeping steady development and operates as an excellent domestic investment organization with an extraordinary return.

Founded in August 2008, Chiron Ventures is an investment firm specializes in innovation and investment in medical health. The company has accumulated rich experience and resources in medical technology development, medical innovation and entrepreneurship, and medical market development, providing substantial support and professional value-added services.